4157 Stock Overview
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
TaiGen Biopharmaceuticals Holdings Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$14.95 |
52 Week High | NT$18.75 |
52 Week Low | NT$13.85 |
Beta | 0.78 |
1 Month Change | 2.05% |
3 Month Change | -2.29% |
1 Year Change | -2.29% |
3 Year Change | -37.84% |
5 Year Change | -16.48% |
Change since IPO | -76.04% |
Recent News & Updates
Shareholder Returns
4157 | TW Biotechs | TW Market | |
---|---|---|---|
7D | -0.7% | -0.5% | 1.8% |
1Y | -2.3% | -22.5% | 28.5% |
Return vs Industry: 4157 exceeded the TW Biotechs industry which returned -22.5% over the past year.
Return vs Market: 4157 underperformed the TW Market which returned 28.5% over the past year.
Price Volatility
4157 volatility | |
---|---|
4157 Average Weekly Movement | 3.0% |
Biotechs Industry Average Movement | 4.5% |
Market Average Movement | 4.4% |
10% most volatile stocks in TW Market | 8.2% |
10% least volatile stocks in TW Market | 2.0% |
Stable Share Price: 4157 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4157's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | n/a | Philip Huang | www.taigenbiotech.com.tw |
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.
TaiGen Biopharmaceuticals Holdings Limited Fundamentals Summary
4157 fundamental statistics | |
---|---|
Market cap | NT$10.73b |
Earnings (TTM) | NT$136.73m |
Revenue (TTM) | NT$123.13m |
78.5x
P/E Ratio87.2x
P/S RatioIs 4157 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4157 income statement (TTM) | |
---|---|
Revenue | NT$123.13m |
Cost of Revenue | NT$11.45m |
Gross Profit | NT$111.69m |
Other Expenses | -NT$25.04m |
Earnings | NT$136.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.19 |
Gross Margin | 90.70% |
Net Profit Margin | 111.04% |
Debt/Equity Ratio | 0% |
How did 4157 perform over the long term?
See historical performance and comparison